Guohong Han

机构：Medical Center Hospital, Xi’an International University · ORCID：0000-0003-4568-3776

发表论文 293 篇 · 总被引 19931 次 · h-index 54

代表论文

• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management (2024 · Hepatology International · 被引 37)
• Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆ (2024 · JHEP Reports · 被引 11)
• Efficacy and Safety of Spontaneous Portosystemic Shunts Embolization for Hepatic Encephalopathy: A Meta-analysis (2025 · Academic Radiology · 被引 3)